• JBM Healthcare published its 2025/2026 annual report, flagging resilient performance as Hong Kong retail conditions improved.
• Proprietary Chinese medicines drove growth, supported by continued momentum in core heritage brands and portfolio expansion.
• Health and wellness revenue fell on product rationalization, partly offset by double-digit growth in Oncotype DX genomic testing.
• Strategy sharpened toward owned brands in cross-border e-commerce, with wider reach via major mainland platforms.
• Acquisitions expanded downstream Chinese medicine clinic services, adding a clinic network to support vertical integration across products, practitioners, and patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JBM (Healthcare) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245633), on July 15, 2026, and is solely responsible for the information contained therein.